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Abstract 
Waldenström’s macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for 
which clearly defined criteria for the diagnosis, initiation of therapy and treatment strategy 
have been proposed as part of the consensus panels of the International Workshops on WM 
(IWWM). At the last IWWM in London 2014 the IWWM-8 task force for the treatment 
recommendations, based on recently published and ongoing clinical trials, answered specific 
questions for updating the IWWM-7 recommendations on the impact of new mutations 
(MYD88, CXCR4) on treatment decisions, the indications of new BCR and proteasome 
inhibitors and the best options to test in future clinical trials. Moreover the identification of 
the common somatic mutation in MYD88 has offered the opportunity for a more targeted 
approach. Therapeutic strategy in WM should be based on individual patient and disease 
characteristics. The immunochemotherapy combinations with rituximab (R) and 
cyclophosphamide/dexamethasone (DRC), or bendamustine (BR) or bortezomib/ 
dexamethasone (BDR) have provided durable responses and are still indicated for most 
patients but the approval of the BTK-inhibitor ibrutinib in the US and in Europe in this setting 
will modify treatment options in both treatment–naïve and relapsing patients. Other BCR-
inhibitors, second-generation proteasome inhibitors (carfilzomib) and mTOR inhibitors are 
promising and may expand future treatment options. In most patients with WM active 
enrollment of patients in clinical trials is highly encouraged. 
Introduction 
Waldenström'smacroglobulinemia (WM) is, according to WHO classification, a 
lymphoplasmacyticlymphoma, in which the bone marrow is infiltrated by IgM-producing 
clonal lymphoplasmacytic cells (1).The Second International Workshop on WM (IWWM-2) 
proposed criteria for the clinical pathological diagnosis and for initiation of therapy in WM 
patients(2,3). IWWM consensus panels have provided treatment recommendations, which 
were last updated in 2008 (IWWM-4) and in 2012 (4-7). As part of its last consensus 
deliberations (IWWM-8, London August 2014), the panel considered the results from phase II 
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studies of several chemo-immunotherapy regimens, novel drugs (alone or with rituximab) and 
of novel targeted agents (everolimus, carfilzomib, ibrutinib) and examined these data and 
updated its recommendations, which are presented herein.  
The use of anti-CD20 monoclonal antibodies is a standard of care in WM patients in first line 
and in relapse. The combination of anti-CD20 monoclonal antibody with chemotherapy or 
with bortezomib remains a recommended therapy in most patients with WM. Most of the 
published series are small phase II trials using rituximab in combination with alkylating agents 
(cyclophosphamide, bendamustine), with purine analogues (fludarabine) with or without 
alkylating agents, and with proteasome inhibitors (bortezomib). The studies with new anti-
CD20 monoclonal antibodies (ofatumumab, obinutuzumab) or with other new monoclonal 
antibodies are scarce. The choice of immuno-chemotherapy depends on the patient 
comorbidities, short and long-term toxicities, necessity for rapid control of the disease, and 
the need of hematopoietic stem cell collection. Despite considerable heterogeneity in biology 
and clinical course, many mature B-cell malignancies are highly sensitive to kinase inhibitors 
that disrupt BCR signalling. Thus, targeted therapy through inhibition of BCR signalling is 
emerging as a new treatment paradigm also for patients with WM. Chemotherapy-free 
combinations with new target agents such as BCR inhibitors are promising.  
I. Treatment indications 
Not all patients with a diagnosis of WM do need immediate therapy. Criteria for the initiation 
of therapy (proposed in the IWWM-2 consensus panel and confirmed in IWWM-8) are IgM 
related complications and/or cytopenias, B symptoms and bulky disease. For patients who do 
not fulfill the criteria, and in whom only laboratory evidence may indicate a possible 
development of progressive disease (such as a minor decrease in hemoglobin level with 
asymptomatic anemia or mild increases in IgM) or mild increase of lymphadenopathy or 
splenomegaly without discomfort for the patient, close observation is recommended (3). 
Plasmapheresis should always and immediately be used for patients with severe 
hyperviscosity. Furthermore this is an important tool to prevent flare in patients with high 
IgM level pre-rituximab administration. Plasmapheresis alone is not an effective treatment 
of the disease and must be followed by a rapidly acting cytoreductive treatment targeting 
the tumor cells. (7). To omit rituximab for the first one - two cycles of chemotherapy is  an 
alternative to induce tumor debulking and reduce the risk of IgM flare.   
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II. Monoclonal antibodies as a single agent 
Treatment strategies and modalities have changed at the beginning of the 21st century with 
the use of the anti-CD20 monoclonal antibody rituximab. Rituximab is widely used in WM 
patients and since 2000, also new monoclonal antibodies, targeting CD20 or other antigens, 
have been investigated. The combination of anti-CD20 monoclonal antibody with 
chemotherapy is still the standard of care and rituximab-based regimens remain the 
commended primary therapy for most patients with WM (7-11). 
 II.1- Rituximab 
Rituximab is a chimeric monoclonal antibody, which targets the CD20 antigen, expressed on B 
cells, including WM cells. Since the beginning of 2000’s, rituximab is widely used in B 
lymphoproliferative diseases. Two schedules of administration were studied in monotherapy 
for WM: the standard one, in which one weekly infusion of 375 mg/m2 is administrated for 4 
weeks, and the extensive one, in which responsive patients received 4 more infusions mostly 
between the 12th and the 16th week after initiation of therapy. In the standard schedule, 
overall response rates (ORR) varied between 27 and 60%, with 27-35% of major response (≥ 
partial response), with a median time to response of 3 months and duration of response (DOR) 
of 8 months, both in previously treated and untreated patients (12,13). Even for patients with 
minor response, an improvement of hemoglobin and platelet counts, and a  reduction of 
lymphadenopathy and splenomegaly was observed. Extensive therapy allowed an ORR 
between 35 and 48%, with a DOR longer than 29 months (14,15). Rituximab is well tolerated; 
however, about 50% of patients will experience a transient increase of the IgM level, named 
IgM-flare. No predicting factors for the development of IgM-flare, like baseline IgM level, 
plasma viscosity level, bone marrow infiltration, or previous therapy, have been identified. 
The IgM-flare-up effect is seen mostly during the first months of treatment and can persist 
until the 4th month. This phenomenon is associated with a higher risk of treatment failure, but 
physicians should be cautious not to interpret this phenomenon hastily as lack of response or 
even progression, because decrease of IgM level can occur slowly. In patients with  baseline 
serum IgM level or serum viscosity higher than 50g/L or 3.5cp respectively, IgM-flare-up can 
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induce hyperviscosity related complications. Such patients at risk should undergo prophylactic 
plasmapheresis, or avoid rituximab during the first one or two courses of chemotherapy until 
IgM levels decline to a safer level (16). Late-onset neutropenia (LON) has also been described 
with rituximab, mostly when combined with chemotherapy (17). The underlying mechanism 
of LON is not understood, but a cellular immune mechanism or antibody-mediated 
complement cytotoxicity have been proposed (18). An association between a specific 
polymorphism in the immunoglobulin G Fc receptor (FCγRIIIaV158 F) and LON was also 
described (19). Predisposing factors of LON in hematologic B-cell malignancies after rituximab 
therapy are previous autologous stem cell transplantation, advanced disease, purine 
analogues exposure, and previous intensive chemotherapy, eventually associated with 
radiotherapy (17). 
Because of the lower chance to respond if the IgM level is high, the long time to response 
and the risk of an IgM-flare, rituximab single agent therapy is now mostly only used for WM 
patients with immunological disorders secondary to the WM, such as anti-MAG neuropathy 
or in patients with low IgM level and cytopenias not eligible for combination immuno-
chemotherapy as frail patients. 
II.2. Ofatumumab 
Ofatumumab is a humanized CD20-directed monoclonal antibody that targets a CD20-region 
at a different epitope than that of rituximab. One phase II trial studied ofatumumab as a 
monotherapy in 37 treatment naïve or previously treated patients. Ofatumumab was given at 
two dose levels and for two blocks of weekly consecutive infusions:  59% of the patients 
achieved at least a minimal response after both cycles (38% a PR), with somewhat higher 
responses at higher doses (47% versus 68%), in therapy-naïve (6/9, 67%) and rituximab-naïve 
(9/12, 75%) patients than in rituximab-exposed patients (13/25, 52%).  But patients 
experienced an IgM flare requiring plasmapheresis also with this anti-CD20 monoclonal 
antibody (20). In patients with intolerance to rituximab, ofatumumab is another therapeutic 
option (21).  
III.  Combinations with rituximab 
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Because rituximab is an active and a non-myelosuppressive agent, its combination with 
various chemotherapeutic agents has been extensively explored in WM. The combination of 
anti-CD20 monoclonal antibody and chemotherapy is considered standard of care in patients 
in first line treatment. The choice of chemotherapy depends on the comorbidities, how fast 
control of the disease is required and the phenotype of the disease. 
III.1 Rituximab + alkylators 
The combination of dexamethasone, rituximab and cyclophosphamide (DRC) has been tested 
in a phase II trial in 72 untreated WM patients. A high response rate (83%) was observed, with 
7% and 67% complete and partial responses, respectively. The 2-year PFS was 67% in all cohort 
and 80% in responders. Median time to response was however long with 4.1 months, 
suggesting that this combination is not appropriate if a rapid control of disease is necessary. 
Toxicities were mild, with only 9% of grade 3-4 neutropenia (24). This study was recently 
updated with a follow up longer than 7years for all patients. Time to treatment failure and 
time to next treatment were 35 and 51 months, respectively. The majority of relapsing 
patients were still sensitive to rituximab-based therapies and long-term toxicity profile was 
favorable with only one case of MDS and two cases of transformation to DLBCL (one after 
exposure to multiple lines of therapy). The causes of death were followed prospectively in this 
study: among 35 patients (49%) who died, 20 (57%) were related and 15 (43%) were unrelated 
to WM. WM-related death at 8 years was 32% and WM-unrelated was 21%. The 8-year OS per 
the ISSWM was 100%, 55% and 27% for low, intermediate or high risk disease 
respectively(p=0.005) (22, 23). 
This update indicates that DRC is an active and safe treatment choice in first line for WM 
with a manageable toxicity, even in frail patients and is widely used in first line in this setting 
III.2. Rituximab + purine analogues  
Most data on fludarabine–based regimens has been discussed in the previous 
recommendation papers in 2009 and 2014 (6, 7). Rituximab, fludarabine and 
cyclophosphamide is one of the most effective and fast acting regimen in relapsed patients 
with the longest PFS (median: 70 months), at least in a historical comparison with other 
salvage regimens (24). 
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Fludarabine-based combinations should be considered in fit patients with 
relapsed/refractory WM. In young patients who are ASCT eligible, stem cells should be 
collected before fludarabine administration. 
III.4. Rituximab + bendamustine 
Rituximab + bendamustine (BR) was compared to RCHOP in a phase 3 open-label trial. A total 
of 546 patients were enrolled in this study for indolent NHL patients, including 41 patients 
with WM (22 treated with BR and 19 with R-CHOP). Patients on the BR arm received 6 cycles 
of bendamustine at 90 mg/m2 on days 1, 2 and rituximab at 375 mg/m2 on day 1 every 4 
weeks. A similar ORR (95%) but with a longer PFS was reported for the RB arm (median 69.5 
months, versus 28.1 months in the RCHOP arm), with a better tolerance of chemotherapy 
(lower rates of grade 3-4 neutropenia, infectious complications and peripheral neuropathies, 
and no alopecia) (25). 
In the salvage setting, the outcome of 30 WM patients with relapsed/refractory disease who 
received bendamustine alone, or with a CD20-directed antibody was reported by Treon et al. 
An overall response rate of 83% and a median progression free survival of 13 months were 
reported in this study. Overall, therapy was well tolerated though prolonged 
myelosuppression occurred in patients who had received prior nucleoside analogue therapy 
[26]. Tedeschi reported an Italian retrospective study in 72 patients with relapsed/refractory 
disease. Two doses of bendamustine were used: 45 patients (63%) received 90 mg/m2 and 22 
(31%) were treated with 70 mg/m2on day 1 and 2 (4 patients received 50 mg/m2 due to 
comorbidities). Overall and major response rates were 80% and 75%. Major toxicity was grade 
3/4 neutropenia occurring in 13% of courses. There was no significant association between 
baseline features or patients' characteristics and response achievement. Median progression-
free survival was not reached after a median follow-up of 19 months (range 3-54). Among 
responders the median time to 50% reduction in serum monoclonal protein was 3 months 
(range 1 – 6). No IgM flare was recorded in any of the patients. Sixty-six percent of patients 
completed the planned 6 courses. Ten patients discontinued due to toxicity (infection in 4 and 
myelosuppression in 6). A better quality of response (CR plus VGPR) was observed in patients 
with an IgM level <3000 mg/dL and in those treated with the higher dosage of B (90 mg/m2).  
Most of the patients received prophylactic growth factors, and grade 3-4 neutropenia 
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developed in 13% of courses, in 36% of patients. None of the patients developed aggressive 
lymphoma or secondary myelodysplastic syndrome/acute myeloid leukemia, but in 3 cases, a 
solid cancer was observed (27).  
BR combination seems to be as effective in treatment-naïve and as in pretreated WM 
patients. Treatment is well tolerated even in elderly patients with limited episodes of 
myelosuppression and infections when compared to purine analogues-based regimens. This 
combination could be an option even in frail patients or in patients with renal impairment 
 
III.5. Rituximab +Bortezomib 
Treon studied rituximab, bortezomib and dexamethasone in combination in 23 untreated 
patients, with administration of intravenous bortezomib at 1.3 mg/m2 and dexamethasone 40 
mg twice a week at day 1, 4, 8, 11, and rituximab 375 mg/m2 at day 11, for 4 cycles as induction 
treatment, and 4 more cycles at 3 months as maintenance treatment. ORR and major response 
rate were 96% and 83% respectively, with a median time to response of 1.4 months, and a 
late improvement of response after treatment discontinuation with a median time to best 
response of 15 months. Sixty percent of patients discontinued treatment after 4 cycles 
because of the development of peripheral neuropathy. The median PFS was 52 months (28). 
Treatment with bortezomib was then reduced to once a week at 1.6 mg/m2 in an attempt to 
reduce the occurrence of peripheral neuropathy, resulting in Grade 2 – 39%; Grade 3 – 30%. 
This schedule of rituximab + bortezomib was studied in first line by Ghobrial in 26 patients, 
with bortezomib 1.6 mg/m2 administrated intravenously at day 1, 8 and 15 during 6 cycles, in 
a 28-day cycle, and rituximab 375 mg/m2 at each cycle during 4 cycles. Eighty-eight percent of 
patients obtained a response, including 65% of major response (58% ≥PR, 8% CRs/nCRs).  The 
1-year event free survival was 79%. Response was obtained on? both IgM serum level and 
tumor mass. Neurologic complications were limited, and no grade 3-4 peripheral neuropathy 
was reported. Grade 3-4 neutropenia was noted in 12% of patients (29). Likewise in 
relapse/refractory patients, ORR was 81% with 51% of major responses and a median PFS of 
15.6 months. Sixteen percent of patients developed a grade 3 neutropenia and a grade 3 
neuropathy occurred in only 5% of patients (30). Dimopoulos reported the efficacy and toxicity 
of bortezomib, rituximab and dexamethasone (BDR) in 59 treatment-naïve  patients. In order 
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to avoid “IgM flare” the first induction cycle consisted of bortezomib (i.v.1.3 mg/m2 days 1, 4, 
8 & 11), followed by four cycles of weekly bortezomib (i.v.1.6 mg/m2 for 4 weeks) with 
rituximab and dexamethasone in cycles 2 and 5. Peripheral neuropathy was observed in 46% 
of the patients (grade≥3 in 7%) but only 5 (8%) discontinued bortezomib due to neuropathy. 
After a minimum follow-up of 32 months, median progression-free survival was 42 months, 3-
year duration of response for patients with PR was 70%, and 3- year survival was 81% (31). In 
contrast to BCR-inhibitors, bortezomib is also effective in vitro on tumor cells with CXCR4 
mutation (32).  
In the last 2014 recommendation on bortezomib the panel wrote   “Neurotoxicity is the 
major concern with bortezomib because underlying IgM-related neuropathy or 
neuropathies due to age-related co-morbidities (such as diabetes) are common. Weekly 
dosing  and subcutaneous administration may reduce rates and severity of neuropathy and 
is explored in a clinical trial (NCT01592981). Bortezomib is not stem cell toxic and long-term 
follow-up in myeloma patients does not suggest a risk for secondary malignancies. 
Prophylaxis against herpes zoster is strongly recommended. Primary therapy with 
bortezomib is recommended for patients with high levels of IgM, with symptoms of or at 
risk of developing hyperviscosity syndrome, symptomatic cryoglobulinemia or cold 
agglutinemia, amyloidosis and renal impairment(7).  
The panel agrees that bortezomib is less neurotoxic given once weekly and by subcutaneous 
route but, in case of urgent reduction of the IgM level, bortezomib could be started at a dose 
of twice a week for one or two cycles and then be changed to once weekly dosing.  
III.6 Rituximab+ Carfilzomib 
Carfilzomib, a second-generation proteasome inhibitor, is associated with a low risk of 
neurotoxicity in multiple myeloma (MM) patients and was recently evaluated in combination 
with rituximab and dexamethasone (CaRD), mainly in untreated WM patients (33). The 
schedule of carfilzomib was attenuated (days 1, 2 & 8, 9) compared to myeloma dosing, and 
maintenance therapy (days 1, 2 only) was given every 8 weeks for 8 cycles. Overall response 
rate was 87% (≥VGPR in 35%), and no grade≥3 neuropathy was observed. With a median 
follow-up of 15.4 months, 20/31 (65%) patients remain progression-free.  
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CaRD therefore could represent an emerging neuropathy-sparing option for proteasome-
inhibitor based therapy for WM. Cardiac toxicity has been reported in 2% of MM patients 
and could be an issue especially in elderly WM patients with pre-existing cardiac conditions 
(34).Other open issues include the optimal dose of carfilzomib (27 mg/m2 vs. higher doses, 
and the schedule of administration, if once per week dosing schedule as developed in MM) 
IV. Maintenance 
One retrospective study used rituximab as maintenance therapy in 86 patients  responsive to 
combination therapy with rituximab.  Maintenance treatment with rituximab seemed to 
extend PFS and OS, without major secondary effects (35). However this result need to be 
confirmed in prospective randomized studies, and the use of rituximab in maintenance 
therapy is still discussed. A randomized prospective study is ongoing in Germany (MAINTAIN 
study, NCT00877214), analyzing the impact of 2-years rituximab maintenance after an 
induction with rituximab + bendamustine in untreated patients. 
The panel agrees that robust data must be available before recommending anti-CD20 
monoclonal antibodies maintenance in this setting 
V. Stem cell transplantation (SCT) for patients with WM 
SCT (stem cell transplantation) remains an option for salvage therapy in WM, particularly 
among younger patients who have had multiple relapses or with primary refractory disease. 
In an European Bone Marrow Transplant Registry study including 615 autologous stem cell 
transplantation (ASCT) in WM patients, the 5-year disease –free survival ( DFS) and overall 
survival (OS) were 46% and 65%, respectively, for patients with predominately multi-relapsed 
or refractory disease who received ASCT (36)  The non-relapse mortality at 1 year was low 
(7%). With a median follow-up of surviving patients of 53 months, the 5-year OS was 65%, DFS 
was 46%, incidence of relapse (IR) was 47% and NRM was 7%.  IR was significantly lower in 
patients receiving ASCT in first response (CR1, VGPR1, PR1) compared to transplantation in 
subsequent complete or partial responses or with refractory disease (39% vs 53%; p=0.001), 
translating into a significant DFS (50% vs 40%, p= 0.004) and OS benefit (71% vs 63%; p= 0.033) 
for the patients transplanted early. As single-hit, ASCT can induce long term response with 
relatively low toxicity and economic burden, and it may serve as benchmark for the upcoming 
novel targeted therapeutics entering the WM / LPL treatment arena. The outcome of 
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previously treated WM patients who received myeloablative and reduced-intensity allogeneic 
transplantation was also reported by the European Bone Marrow Transplant Registry (37).  
The ORR was 76%, and the 5-year PFS and overall survival rates were 56% and 62%, 
respectively. Among patients who received reduced-intensity allogeneic transplantation, 
similar PFS and overall survival rates were observed (49% and 64%). Non-relapse mortality at 
3 years was high, 33% and 23% for myeloablative and reduced-intensity allogeneic 
transplantation, respectively. SCT should be discussed in very selected cases currently uneasy 
not easy? to identify, taking the numerous available treatment options into account and 
should be preferably considered in the context of clinical trials. 
VI. New compounds  
VI.1 Lenalidomide 
In a phase I/II study lenalidomide monotherapy was used at low dose (starting at 15 mg) (trial 
RV-WM-0426) in seventeen previously treated patients (38). At the highest dose tested, 20 
mg, dose limiting toxicities occurred thus the dose of lenalidomide chosen for further testing 
was 15 mg/day for 21 days out of 28. Seven out of 14 (50%) patients completed one year of 
single agent lenalidomide treatment at 15mg/ day. In an intent-to-treat analysis (n= 17) single 
agent lenalidomide provided an overall response (MR and better) of 29%. Interestingly, all 
responses were obtained from cycle 9 to 12, which implies a potential immunological effect 
of lenalidomide in WM, on top of the direct antitumor and stromal inhibition mechanisms of 
action. A flare effect (transient initial increase of the M spike) was observed in 3 patients. With 
a median follow-up of 36 months, median TTP was 16 months (95%CI 5.5-26) and the 5-year 
OS was 91%. The most frequent AEs≥ grade 3 at 15mg were 14% anemia and 43% neutropenia; 
no grade 3 thrombocytopenia was reported. The combination of rituximab and lenalidomide 
25 mg daily for 3 weeks followed by 1 week rest was studied by Treon, in 16 patients (12 in 
first line). ORR was 50%, and only 1 case of neuropathy was noted. However, 88% of patients 
had reduction of their hematocrite, in spite of lenalidomide dose reduction to 5 mg. Thus, 
lenalidomide with rituximab was associated with significant hematologic toxicity (39). 
Based on the current data and the potential toxicity observed with lenalidomide, this drug 
should only be considered in the context of a clinical trial, until further data are available. 
VI. 2 mTOR Inhibitor  
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Ghobrial reported the long–term results of a phase II trial with everolimus in 60 
relapsed/refractory patients (40). The response rate was 50% of PR and 23% of MR.  The 
median time to response was 2months and the median PFS was 21 months.  Toxicity was 
hematologic with 27% and 20% of grade3-4 anemia and thrombocytopenia. Pulmonary 
toxicity was also reported. 
VI.3 New monoclonal antibodies 
VI.3.1 Anti-BLyS monoclonal antibody 
The B-lymphocyte stimulator (BLyS) protein is a cytokine belonging to the tumor necrosis 
factor (TNF) family, implicated in B-cell survival and maturation, and is over expressed in WM. 
One phase II study used the anti-BLyS monoclonal antibody, belimumab, in 12 patients with 
WM. No objective response was reported but 10 patients had stable disease. Belimumab has 
not been studied in combination therapy yet (41). 
VI.3.2 Ublituximab 
Ublituximab is a novel chimeric anti-CD20 monoclonal antibody that has a high affinity for NK 
FcγRIIIa receptors. Preclinical studies showed that ublituximab is more efficient than rituximab 
in inducing NK cell degranulation and antibody-dependent cellular cytotoxicity (42). A Phase 
I/II trial with single agent ublituximab in patients with rituximab relapsed/refractory NHL, 
including WM patients is currently ongoing (NCT 01647971). 
The panel agrees that scarce data are available in patients treated with new monoclonal 
anti-CD20 or other target directed antibodies. Phase II studies are needed in combination 
with chemotherapy, proteasome inhibitors or BCR inhibitors to evaluate their activity in 
different disease settings as well as their safety. 
 
VI.4 B-Cell Receptor (BCR) pathway inhibitors 
Ibrutinib is a BTK inhibitor effective in high-risk CLL and in mantle cell lymphoma patients.  
There is a strong rationale to use this drug in WM patients regarding the interaction of BTK 
and MYD88 pathway. The mutation in MYD88 enhances the proliferation of WM cells, by 
activating NF kappa B pathway via BTK and BCR activation. Treon recently reported the results 
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of a prospective study of ibrutinib in 63 symptomatic patients with WM who had received at 
least one previous treatment (43). The median time to at least a minor response was 4 weeks. 
The overall response rate was 91%, and the major response rate was 73%.  The estimated 2-
year progression-free and overall survival rates among all patients were 69% and 95%, 
respectively. Treatment-related toxic effects of grade 2 or higher included neutropenia (in 
22% of the patients) and thrombocytopenia (in 14%), which were more common in heavily 
pretreated patients; post procedural bleeding (in 3%); epistaxis associated with the use of fish-
oil supplements (in 3%); and atrial fibrillation associated with a history of arrhythmia (5%). The 
results of therapy with ibrutinib as a single agent are impressive. However, the experience is 
still limited and the side effects and drug interactions of this drug must be stressed, especially 
in the elderly population. The off target effect of ibrutinib on platelet aggregation with 
bleeding complications has been described in CLL trials (44). The use of ibrutinib in patients 
requiring other anticoagulants or medicinal products that inhibit platelet function may 
increase the risk of bleeding, and particular care should be taken if anticoagulant therapy is 
used. Moreover acquired von Willebrand disease   associated with a high IgM level and can be 
responsible for bleeding (45). The panel recommends to test the von Willebrand activity in 
patients with high IgM level or with bleeding before starting ibrutinib and to perform 
plasmapheresis for improving the von Willebrand factor level at the beginning of ibrutinib 
administration. The efficacy of the drug on IgM levels is rapid (4 weeks to reach a minor 
response) allowing stopping plasmapheresis. In case of surgery, ibrutinib should be held at 
least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of 
bleeding. Another off- target effect is through the inhibition of cardiac PI3K-AKt pathway with 
a risk of atrial fibrillation (46). In patients with preexisting atrial fibrillation requiring 
anticoagulant therapy, alternative treatment options to ibrutinib should be considered. In 
patients who develop atrial fibrillation on therapy with ibrutinib a thorough assessment of the 
risk for thromboembolic disease should be undertaken. In patients at high risk and where 
alternatives to ibrutinib are no suitable, tightly controlled treatment with anticoagulants 
should be considered. Ibrutinib produces a mild decrease in QT interval (mean 7.5 ms). 
Underlying mechanism and safety relevance of this finding is not known. Clinicians should use 
clinical judgment when assessing whether to prescribe ibrutinib to patients at risk from further 
shortening their QT duration. Randomized studies are ongoing comparing the efficacy of R+ 
placebo versus R+ ibrutinib in relapsing and in treatment-naïve patients (NCT02165397). 
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Novel BTK inhibitors are in clinical development and may offer additional choices if they have 
a different toxicity profile (CC-292 (AVL-292), and ONO-4059, ACP-196) 
 
Ibrutinib is definitively an option in symptomatic WM patients. This drug was approved in 
first line and in relapsing patients by the FDA in the US in February 2015 and by the EMA in 
July 2015.  However, the optimal time point of therapy with ibrutinib (in first line, relapse 
or later) and the optimal combination (with rituximab or other anti-CD20, with PI inhibitors 
such as bortezomib or carfilzomib) is still under investigation. The costs of ibrutinib 
monotherapy (and potential combinations) against the benefit in terms of PFS or OS must 
be weighed.  
The MYD88 mutation is observed in almost all patients with WM and results in tonic MYD88-
IRAK signaling, which activates the NF-κB and MAPK pathways supporting growth and survival 
of WM cells. Of note MYD88 wild type patients had a lower rate and quality of response to 
ibrutinib than MY88 mutated patients (47). The efficacy of this drug may be also depend on 
CXCR4 mutation, with a lower response rate in mutated patients asking the question whether 
treatment should be stratified according to the CXCR4 mutational status. CXCR4 mutations 
are observed in 30% of the patients and are associated with a significant but lower response 
rate to BCR-inhibitors in vitro and in vivo (35,43). The interaction of the chemokine CXCL12 
with CXCR4 regulates homing of tumor cells in bone marrow in WM. The role of the 
CXCR4/CXCL12 axis in WM was already pointed out by Ngo et al. in WM CXCL12/CXCR4 axis 
interacts with VLA-4 in regulating adhesion of tumor cells to BM stromal cells (48).  The 
distribution and the clinical influence of the CXCL12 (−801GA) polymorphism was shown by 
Poulain et al., documenting that CXCL12 (−801GG) WM patients show a shorter median 
survival after initiation of first line therapy than remaining patients (49). The CXCR4 mutation 
is more difficult to test than MYd88 mutation and requires routinely Sanger sequencing with 
sufficient tumor cells for analysis. 
 
The panel recommends testing MYD88 and CXCR4 mutations in clinical trials for their impact 
on the quality of the response but more data are needed for tailoring treatment options to 
MYD88 and CXCR4 results  
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Idelalisib is a BCR inhibitor, which targets PI3Kinase delta and was approved for treatment in 
relapsed CLL and follicular lymphoma. Few data are available in WM. Gopal reported the 
efficacy of rituximab and idelalisib combination in ten WM patients with 80% overall response 
rate and a median PFS of 22 months. Trials are ongoing in this setting in naïve-treated and 
relapsing patients in combination with anti-CD20 antibodies. Grade 3-4 adverse effects of 
idelalisib are diarrhea (19%) neutropenia (28%) pneumonia (16%) and elevated ALT/AST (12%) 
(50)  
The panel agrees there are more data needed before recommending this combination in 
relapsing/refractory patients with WM   
 
 
VII. The future options  
Which clinical trials should be prioritized in the front line setting for symptomatic WM 
patients? 
Many options are available in first line: immunochemotherapy with anti-CD20 monoclonal 
antibodies or the combination of anti-CD20 MoAbs with proteasome inhibitors. The aim of 
the first line treatments is to reach a high response rate but?with a prolonged PFS. The panel 
agrees there is need to perform clinical trials with chemo-free combinations with new 
compounds alone or in combination with anti-CD20 antibodies. Ibrutinib is approved in front-
line setting and front line trials with BCR inhibitors are needed for assessing the efficacy and 
tolerability of this drug in treatment-naïve patients alone and in particular in combinations. 
 
Which clinical trials should be prioritized in the salvage setting for symptomatic WM 
patients? 
The panel agrees with the interest of BCR- inhibitors and new compounds in patients in relapse 
setting. Combination with proteasome inhibitors would be of interest for overcoming 
resistance, interfering with the two key pathways that are affected by MYD88.  A randomized 
trial comparing the efficacy of BCR inhibitors to that of BCR-inhibitors+ proteasome inhibitors 
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could answer this question. Obinutuzumab with its shown efficacy in CLL and also now in 
follicular lymphoma will be of interest as a combination partner in WM.  
VII. Conclusion  
Treatment goals may differ significantly for different patients (Tables 1 and 2). Many patients 
do not succumb to WM but to other causes as previously shown in retrospective and 
prospective studies. Thus, the goal of therapy is different in patients who are young and in 
whom we could consider intensified combinations with curative intent or long maintained 
deep remissions. New agents have real promise and we have to utilize them in combination 
for an abbreviated course of treatment to achieve the best response rate and duration of 
response and in parallel limiting costs. The combinations can include monoclonal antibodies, 
new compounds and also chemotherapy in a curative strategy. 
In elderly patients, who comprises the majority of WM patients, toxicity of the regimen (both 
short term and long term) must be considered first, especially in those who do not require 
immediate response with intensive regimens because e.g. lack of bulky disease or IgM – 
related complications. Since many patients, especially elderly ones, will benefit from low 
toxicity regimens with adequate tumor control, such therapeutic approaches should be 
considered as primary choices. The cost and effectiveness of such regimens must be weighed 
against that of other new therapies. 
In the salvage setting, especially for patients with disease refractory to standard chemo-
immunotherapy, there is a need for development of novel therapies and approaches. Such 
approaches may include new monoclonal antibodies, BTK-inhibitors or PI3kdelta-inhibitors, 
BCL2-inhibitors, immune-checkpoint modifiers, etc. (51). Recently, impressive results has 
been seen in other indolent B – cell lymphomas, using PD1 inhibitors in combination with 
rituximab, following the concept to exploit the maximum of ADCC of rituximab by inhibiting 
co-inhibitory molecules on effector cells (52).  Combination strategies that aim to overcome 
drug resistance (for example PI inhibitors with BTK inhibitors) may be explored in clinical trials. 
Collectively, immunochemotherapy is still the backbone of treatment for the majority of 
patients today. Rituximab in combination with chemotherapy is among the most effective 
treatment in WM and is uniformly recommended in national and international guidelines for 
first line and salvage treatment in this disease. Rituximab single agent offers the possibility to 
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elderly patients with co-morbidities to control their disease, although to a lesser extent than 
rituximab/chemotherapy and also with a prolonged time to first response. All this shows that 
immunotherapy will stay one of the key therapeutic principles in patients with WM in the 
future. Despite this, the emergence of drugs such as ibrutinib most likely heralds a new era of 
treatment in WM and novel signal transduction inhibitors will surely enrich our arsenal to fight 
WM in the future. 
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Table 1: Modifications of the recommendations for initial therapy according to clinical 
conditions of patients with WM. 
Clinical condition Recommendation 
2015/2016 [IWWM 8] 
Recommendation  2012 
[IWWM 7](7)  
Recommendation  
2009 [IWWM 4] (6) 
Cytopenias DRC 
Bendamustine-Rituximab 
Bortezomib/Rituximab 
Ibrutinib  
DRC,  
Bendamustine-Rituximab,  
Bortezomib-Rituximab 
DRC 
Thalidomide+Rituximab 
High M-protein, auto 
transplant candidate  
Bendamustine-Rituximab,  
Bortezomib-Rituximab 
 Ibrutinib 
Bendamustine -Rituximab,  
Bortezomib-Rituximab 
R-CHOP, DRC 
High M-protein, non-
autotransplant 
candidate 
Bendamustine-Rituximab,  
Bortezomib-Rituximab 
Ibrutinib  
Bendamustine-Rituximab,  
Bortezomib-Rituximab 
Nucleoside analogs + 
rituximab; nucleoside 
analogs + rituximab + 
cyclophosphamide 
 
Comorbidities and 
cytopenias 
Rituximab 
Ibrutinib   
 Rituximab  
Older age, slow 
progression, 
candidate for oral 
therapy  
Ibrutinib  
Oral fludarabine 
Oral fludarabine Cladribine 
IgM-related 
Peripheral 
Neuropathy 
Rituximab 
DRC 
Ibrutinib  
Rituximab+Fludarabine 
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Table 2: Recommendations for initial therapy of patients with WM, based on the individual 
patient characteristics 
 Primary choice(s) Alternative (s) 
Patients with WM 
related cytopenias or 
organomegaly 
 
DRC 
Bendamustine/rituximab 
Ibrutinib 
 
Bortezomib/rituximab 
Patients with 
symptomatic 
hyperviscosity, 
cryoglobulinemia or 
cold agglutinemia 
Bortezomib followed by 
bortezomib/rituximab 
Bendamustine / rituximab 
Ibrutinib 
Fludarabine/rituximab+/- 
cyclophosphamide 
Patients with 
paraprotein related 
neuropathy 
Rituximab alone 
DRC 
Ibrutinib 
 
Fludarabine/R 
Bendamustine / rituximab 
Carfilzomib, dexa, rituximab 
Elderly patients with 
poor PS 
DRC 
Oral fludarabine 
Ibrutinib  
 
Rituximab monotherapy 
Chlorambucil 
Elderly  patients not 
eligible for systemic IV 
therapy  
Oral fludarabine 
Ibrutinib  
Chlorambucil 
Young patients eligible 
for ASCT 
DRC 
Bortezomib/rituximab 
Ibrutinib 
Bendamustine/rituximab 
R-CHOP 
 
  
20 
 
 
 
References 
1. Swerdlow SH. vol. 2. Geneva: World Health Organization; 2008. WHO Classification 
of Tumours of Haematopoietic and Lymphoid Tissues, 
2. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of 
Waldenstrom’smacroglobulinemia: consensus panel recommendations from the 
Second International Workshop on Waldenstrom’sMacroglobulinemia. SeminOncol. 
2003;30(2):110–115.  
3. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate 
therapy in Waldenstrom’smacroglobulinemia: consensus panel recommendations 
from the Second International Workshop on Waldenstrom’sMacroglobulinemia. 
SeminOncol. 2003;30(2):116–120.  
4. Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in 
Waldenstrom’smacroglobulinemia: consensus panel recommendations from the 
Second International Workshop on Waldenstrom’sMacroglobulinemia. SeminOncol. 
2003;30(2):121–126.  
5. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations 
from the Third International Workshop on Waldenstrom’smacroglobulinemia. 
Blood. 2006;107(9):3442–3446. [ 
6. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations 
from the Fourth International Workshop on Waldenstrom’sMacroglobulinemia. J 
Clin Oncol. 2009;27(1):120–126.  
7. Dimopoulos MA,  KastritisE,  Owen RG, , Kyle RA,, Landgren 0,Morra E et al. , 
Treatment recommendations for patients with Waldenström’sMacroglobulinemia 
(WM) and related disorders: consensus from the Seventh International Workshop on 
WM. Blood2014:124(9):1404-11. 
8. Buske C, Leblond V. How to manage Waldenstrom'smacroglobulinemia.Leukemia. 
2013 4:762-72 
9. Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M; ESMO Guidelines 
Working Group. Waldenstrom'smacroglobulinaemia: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and follow-up.AnnOncol. 2013 Suppl 6:vi155-9. 
10. Buske C, Seymour J. Immunochemotherapy in Waldenströmmacroglobulinemia - 
still the backbone of treatment. Leuk Lymphoma. 2015 Jun 9:1-6. [Epub ahead of 
print] 
11. Treon SP: How I treat Waldenstrom’smacroglobulinemia. Blood. 2015 May 22. pii: 
blood-2015-01-553974. [Epub ahead of print] 
12. Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, et al. CD20-Directed 
Antibody-Mediated Immunotherapy induces responses and facilitates hematologic 
recovery in patients withWaldenstrom’sMacroglobulinemia. J Immunother.2001;24: 
272–79  
21 
 
13. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, and Greipp PR. Multicenter phase 
2 trial of rituximab for Waldenströmmacroglobulinemia (WM): an Eastern 
Cooperative Oncology Group Study (E3A98). Leuk.Lymphoma. 2004; 45: 2047–2055  
14. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V et al. 
Treatment of Waldenström’smacroglobulinemiawith rituximab. J ClinOncol. 2002; 
20 : 2327–33 
15. Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, et al. 
Extended rituximab therapy in Waldenström’smacroglobulinemia. Ann Oncol.  2005; 
16: 132–38 
16. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, VesoleDH,et al. Initial 
immunoglobulin M “flare” after rituximab therapy in patients diagnosed with 
Waldenstrommacroglobulinemia: an Eastern Cooperative Oncology Group Study. 
Cancer 2004; 101: 2593–2598  
17. Wolach O, Bairey O, and Lahav M. Late-onset neutropenia after rituximab treatment: 
case series and comprehensive review of the literature. Medicine(Baltimore) 2010; 
89: 308–318  
18. Wolach O, Shpilberg O, and Lahav M. Neutropenia after rituximab treatment: new 
insights on a late complication. Curr.Opin.Hematol.2012; 19: 32–38  
19. Li SC, Chen YC, Evens AM, Lee CC, Liao HF, Yu CC, Tung YT, et al. Rituximab-induced 
late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc 
receptor FcγRIIIa 158(V/F) polymorphism. Am. J. Hematol.2010; 85:810–812  
20. Furman RR, Eradat H, Switzky J. A Phase II Trial of Ofatumumab in Subjects with 
Waldenstrom'sMacroglobulinemia. Blood. 2011:  118: Abstract 3701 
21. Kanan S, Meid K, Treon SP, Castillo JJ. Clinical characteristic of Rituximab intolerance 
in patients with Waldenstrom’smacroglobulinemia. Blood 2014, 124: abstract 2610  
22. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G,  
et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, 
rituximab, and cyclophosphamide. J. Clin. Oncol.2007; 25 : 3344–49  
23.  Kastritis E Blood. 2015 Sep 10;126(11):1392-4 
24. Tedeschi A, Ricci F, Goldaniga MC, Benevolo G, Varettoni M, Motta M, et al. 
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of 
Waldenström'smacroglobulinemia.Clin Lymphoma Myeloma Leuk. 2013 ; 2:208-10 
25. Rummel MJ, Niederle N, MaschmeyerG,Banat GA, vonGrünhagen U, LosemC,  et al. 
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for 
patients with indolent and mantle-cell lymphomas: an open-label, multicentre, 
randomised, phase 3 non-inferiority trial. Lancet.2013; 381:1203–1210  
26. Treon SP, Hanzis C, Tripsas C, Ioakimidis L, Patterson CJ, Manning RJ, Sheehy 
P.Bendamustine therapy in patients with relapsed or refractory 
Waldenström'smacroglobulinemia.Clin Lymphoma Myeloma Leuk. 2011 ;1:133-5 
27. Tedeschi A, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, et al. 
Bendamustine and rituximab combination is safe and effective as salvage regimen in 
Waldenström macroglobulinemia.Leuk Lymphoma. 2015 Mar 14:1-6. 
28. Treon SP, Ioakimidis L, SoumeraiJD,Patterson CJ, Sheehy P, Nelson M, et al. Primary 
therapy of Waldenströmmacroglobulinemia with bortezomib, dexamethasone, and 
rituximab: WMCTG clinical trial 05-180. J. Clin. Oncol. 2009; 27: 3830–35  
22 
 
29. Ghobrial IM, Xie W, PadmanabhanS,BadrosA,Rourke M, Leduc R ,et al. Phase II trial 
of weekly bortezomib in combination with rituximab in untreated patients with 
WaldenströmMacroglobulinemia. Am. J. Hematol. 2010; 85: 670–74  
30. Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II 
trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and 
refractory Waldenstrommacroglobulinemia. J. Clin. Oncol. 2010; 28: 1422–28 
31. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis 
E, et al. Primary therapy of Waldenstrommacroglobulinemia (WM) with weekly 
bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a 
phase 2 study of the European Myeloma Network (EMN) Blood. 2013 122:3276-82 
32. Hunter ZR, Liu X, Xu L, Yang G, Chen J,et al. The WHIM-like CXCR4 (S338X) somatic 
mutation activates AKT and ERK, and promotes resistance to ibrutinib and other 
agents used in the treatment of Waldenstrom'sMacroglobulinemia.Leukemia2015 
29:169-76. 
33. Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, et al. Carfilzomib, 
rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing 
approach for treating Waldenström'smacroglobulinemia.Blood 2014 ;124: 503-10. 
34. Siegel D,  Martin T, Nooka  A, Harvey RD, Vij R, Niesvizky R et al.  Integrated safety 
profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 
II clinical studies.Haematologica  2013;  98: 1753-1761 
35. Treon SP, Hanzis C, Manning RJ,Ioakimidis L, Patterson CJ, Hunter ZR,  et al. 
Maintenance rituximab is associated with improved clinical outcome in rituximab 
naïve patients with WaldenstromMacroglobulinaemia who respond to a rituximab-
containing regimen. Br. J. Haematol2011; 154: 357–62 
36. Kyriakou C, Boumendi A, Finel H, Vernant JP, Cornelissen JJ,  Thieblemont C et al. 
Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with 
Waldenstrom’sMacroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a 
Risk Factor Analysis By the European Society for Blood and Marrow Transplantation 
(EBMT) Lymphoma Working Party. Blood 2014; 124: 678 
37. Kyriakou C, Canals C, Cornelissen JJ, Socie G, Willemze R, Ifrah N, et al.Allogeneic 
stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report 
from the Lymphoma Working Party of the European Group for Blood and Marrow 
Transplantation. J Clin Oncol 2010 28: 4926-4934. 
38. Fouquet G,  GuidezS, Petillon MO,, Louni C , Ohuba B, Dib M et al. Lenalidomide Is 
safe and active in Waldenstrom Macroglobulinemia.  Am J Hematol 2015 in press 
39. Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, IoakimidisL,et al. 
Lenalidomide and rituximab in Waldenstrom’smacroglobulinemia. Clin. Cancer Res. 
2009; 15: 355–60  
 
40. Ghobrial IM, Witzig TE, Gertz M, LaPlant B, Hayman S, Camoriano J et al. Long-term 
results of the phase II trial of the oral m-TOR inhibitor everolimus( RAD 001) in 
relapsed or refractory WaldenstromMacroglobulinemia. Am J Hematol 2014 89: 
237-242. 
41. Bishton M, Spencer A, Dickinson M, and Ritchie D. A Single-Arm, Phase II Study of 
the Anti-Blys Monoclonal Antibody Belimumab in Symptomatic 
WaldenstromMacroglobulinemia.Clin Lymphoma Myeloma Leuk.2013;13: 575-78 
23 
 
42. Le Garff-Tavernier M, Herbi L, de Romeuf C, Azar N, Roos-Weil D, Bonnemye P, et al 
The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer 
phenotypic features in Waldenström macroglobulinemia.Haematologica. 2015; 100: 
147-51.  
43. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R et al. Ibrutinib in 
previously treated Waldenstrom macroglobulinemia. N Engl J Med 2015;  372:1430-
40. 
44. Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS et al. Ibrutinib 
treatment affects collagen and von Willebrand factor-dependent platelet functions. 
Blood. 2014; 124: 3991-5. 
45. Hivert B, Caron C, Petit S, Charpy C, Fankam-Siaka C, Lecocq Set al. Clinical and 
prognostic implications of low or high level of von Willebrand factor in patients with 
Waldenstrom macroglobulinemia. Blood 2012; 120:3214-21. 
46. McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ3, Tam CS. Ibrutinib increases 
the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt 
signaling. Blood. 2014;124:3829-30 
47. MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. 
Treon SP, Xu L, Hunter Z. N Engl J Med. 2015; 373:584-6 
48. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J et al. SDF-1/CXCR4 and VLA-4 
interaction regulates homing in Waldenstrom macroglobulinemia.Blood. 2008; 
112:150-8.  
49. Poulain S, Ertault M, Leleu X, Coiteux V, Fernandes J, Stalnikiewicz L et al.  
SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment 
initiation in Waldenstrom macroglobulinemia.Leuk Res. 33: 1204-7.  
50. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ et al. 
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. NEngl J 
Med. 2014; 370: 1008-18. Jan 22 
51.  Tam CS: ABT-199 (GDC-0199) achieves deep and durable responses in patients with 
heavily pretreated Waldenström Macroglobulinemia (WM): Preliminary results from 
an ongoing phase I study. Proc 8th. International Workshop on Waldenström  
Macroglobulinemia London Aug 14-16 2014 (Abstr W3) 
52. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of 
PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed 
follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014; 
15:69-77. 
 
 
 
